



Announcing the Launch of  
 **Atropine Multi-Dose Vials**   
Products Available

Strength	Package
8mg/20mL	Multi-Dose Vials in Pack of 10 Vials

**FIRST GENERIC IN THE MARKET**

- Accord Healthcare is proud to announce that it has received final FDA approval and been granted Competitive Drug Therapy “CGT” exclusivity for its Atropine Sulfate Multi-Dose Vials ANDA (Abbreviated New Drug Application). Atropine Multi-Dose is available in 8mg/20mL vials and distributed in packs of 10. CGT designation is made by FDA when there is inadequate generic competition in a drug product market. Companies that successfully bring CGT designated drugs to market first receive 180 days of exclusivity, during which time no other generic can enter the market. Accord launched Atropine Multi-Dose Vials on March 25, 2021. Atropine Multi-Dose Vials are currently on the FDA Drug Shortage List.
- Atropine is a medication used to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate, and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle.
- This offering complements Accord’s previous January 2021 launch of Atropine Single-Dose Vials, available in 0.4mg/mL and 1mg/mL, 1 mL vials.
- Accord would like to thank all of its team members for making the launch of this important medication possible.

Please visit the [Product Section](#) of our website for more information.